TABLE 1.
Patient demographic and clinical characteristics.
| Development dataset (n = 776) | Validation dataset (n = 145) | Overall (N = 921) | |
|---|---|---|---|
| Sex, n (%) | |||
| Female | 475 (61.2%) | 69 (47.6%) | 544 (59.1%) |
| Age (year) | |||
| Median (IQR) | 33.0 (23.0, 47.0) | 31.0 (23.0, 45.0) | 33.0 (23.0, 47.0) |
| Ethnicity, n (%) | |||
| Han Chinese | 748 (96.4%) | 138 (95.2%) | 886 (96.2%) |
| Other | 28 (3.6%) | 7 (4.8%) | 35 (3.8%) |
| Weight (kg) | |||
| Median (IQR) | 66.0 (57.0, 79.0) | 66.0 (58.0, 79.0) | 66.0 (57.0, 79.0) |
| Lean body weight (kg) | |||
| Median (IQR) | 44.2 (38.0, 55.0) | 49.8 (38.4, 58.9) | 44.8 (38.0, 55.9) |
| Height (cm) | |||
| Median (IQR) | 165 (160, 172) | 169 (160, 175) | 166 (160, 173) |
| Smoking status, n (%) | |||
| Yes | 699 (90.1%) | 125 (86.2%) | 824 (89.5%) |
| No | 77 (9.9%) | 18 (12.4%) | 95 (10.3%) |
| Missing | 0 (0%) | 2 (1.4%) | 2 (0.2%) |
| Albumin (g/L) | |||
| Median (IQR) | 41.0 (39.0, 43.0) | 42.8 (40.9, 44.8) | 41.0 (39.0, 43.0) |
| Creatinine clearance (mL/min) | |||
| Median (IQR) | 116 (95.3, 144) | 116 (969, 143) | 116 (95.6, 144) |
| Estimated GFR* (mL/min/1.73 m2) | |||
| Median (IQR) | 114 (101, 130) | 110 (98.8, 122) | 113 (101, 128) |
| Stages of CKD, n (%) | |||
| G1 | 691 (89.0%) | 128 (88.3%) | 819 (88.9%) |
| G2 | 80 (10.3%) | 17 (11.7%) | 97 (10.5%) |
| G3a | 5 (0.6%) | / | 5 (0.5%) |
| G3b | / | / | / |
| G4 | / | / | / |
| G5 | / | / | / |
| Proportion with eGFR>130 mL/min/1.73 m2, n (%) | |||
| 197 (25.4%) | 17 (11.7%) | 214 (23.2%) | |
| Co-administration with Lithium, n (%) | |||
| Yes | 96 (12.4%) | 12 (8.3%) | 108 (11.7%) |
| Daily Dose (mg) | |||
| Mean (SD) | 566 (264) | 570 (276) | 567 (266) |
| Median (IQR) | 575 (358, 763) | 600 (330, 800) | 575 (353, 770) |
| Range (Min, Max) | 1,090 (100, 1,190) | 1,170 (50, 1,220) | 1,170 (50, 1,220) |
| Amisulpride plasma concentration (ng/mL) | |||
| Mean (SD) | 421 (298) | 379 (269) | 414 (294) |
| Median (IQR) | 358 (178, 615) | 319 (168, 518) | 352 (175, 607) |
| Amisulpride dose-normalized plasma concentration (ng/mL/mg) | |||
| Mean (SD) | 0.74 (0.432) | 0.70 (0.449) | 0.73 (0.434) |
| Median (IQR) | 0.67 (0.428, 0.946) | 0.58 (0.390, 0.900) | 0.65 (0.422, 0.940) |
*eGFR calculated using the CKD-EPI equation without the race component.
Abbreviation: BUN, blood urea nitrogen; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation.